Ecaterina Ileana Dumbrava, MD, discusses the rationale for combing BDC-1001, a HER2-targeting TLR7/8 immune-stimulating antibody conjugate with an immune checkpoint inhibitor.
Ecaterina Ileana Dumbrava, MD
Advertisement
Ecaterina Ileana Dumbrava, MD, is an assistant professor in the Department of Investigational Cancer Therapeutics of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.
Articles by Ecaterina Ileana Dumbrava, MD
Advertisement
Latest Updated Articles
Rationale for Adding BDC-1001 to Immune Checkpoint Inhibitor Therapy in HER2+ Breast CancerPublished: February 10th 2021 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Poll Results Reveal Readers’ Top Abstracts at ASH 2025
2
FDA Approves Liso-Cel as First CAR T-Cell Therapy for Marginal Zone Lymphoma
3
Lurbinectedin Contributes to Maintenance of Response in ES-SCLC
4
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
5
